These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 30922248)

  • 21. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
    Pinter M; Sieghart W; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Plank C; Peck-Radosavljevic M
    Oncologist; 2009 Jan; 14(1):70-6. PubMed ID: 19144684
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma].
    Xu L; Li P; Lin XJ; Yuan YF; Zhang YQ; Chen MS
    Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):58-61. PubMed ID: 19538872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
    Lee SH; Song IH; Noh R; Kang HY; Kim SB; Ko SY; Lee ES; Kim SH; Lee BS; Kim AN; Chae HB; Kim HS; Lee TH; Kang YW; Lee JD; Lee HY
    BMC Cancer; 2015 Apr; 15():236. PubMed ID: 25885683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma.
    Greten TF; Forner A; Korangy F; N'Kontchou G; Barget N; Ayuso C; Ormandy LA; Manns MP; Beaugrand M; Bruix J
    BMC Cancer; 2010 May; 10():209. PubMed ID: 20478057
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognosis of patients with advanced hepatocellular carcinoma who failed first-line systemic therapy.
    Shao YY; Wu CH; Lu LC; Chan SY; Ma YY; Yen FC; Hsu CH; Cheng AL
    J Hepatol; 2014 Feb; 60(2):313-8. PubMed ID: 24036008
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma.
    Sanoff HK; Kim R; Ivanova A; Alistar A; McRee AJ; O'Neil BH
    Invest New Drugs; 2015 Apr; 33(2):505-9. PubMed ID: 25613083
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
    Zhu AX; Park JO; Ryoo BY; Yen CJ; Poon R; Pastorelli D; Blanc JF; Chung HC; Baron AD; Pfiffer TE; Okusaka T; Kubackova K; Trojan J; Sastre J; Chau I; Chang SC; Abada PB; Yang L; Schwartz JD; Kudo M;
    Lancet Oncol; 2015 Jul; 16(7):859-70. PubMed ID: 26095784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-world outcome of immune checkpoint inhibitors for advanced hepatocellular carcinoma with macrovascular tumor thrombosis.
    Tsai HM; Han MZ; Lin YJ; Chang TT; Chen CY; Cheng PN; Chuang CH; Wu IC; Chen PJ; Kang JW; Chiu YC; Chiu HC; Chien SC; Kuo HY
    Cancer Immunol Immunother; 2021 Jul; 70(7):1929-1937. PubMed ID: 33409737
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Icaritin Exacerbates Mitophagy and Synergizes with Doxorubicin to Induce Immunogenic Cell Death in Hepatocellular Carcinoma.
    Yu Z; Guo J; Hu M; Gao Y; Huang L
    ACS Nano; 2020 Apr; 14(4):4816-4828. PubMed ID: 32188241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials.
    Lee DW; Jang MJ; Lee KH; Cho EJ; Lee JH; Yu SJ; Kim YJ; Yoon JH; Kim TY; Han SW; Oh DY; Im SA; Kim TY
    Br J Cancer; 2016 Nov; 115(10):1201-1205. PubMed ID: 27736843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma.
    Lee DW; Lee KH; Kim HJ; Kim TY; Kim JS; Han SW; Oh DY; Kim JH; Im SA; Kim TY
    BMC Cancer; 2018 Mar; 18(1):252. PubMed ID: 29506478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
    Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
    Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Arizumi T; Ueshima K; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Sakurai T; Nishida N; Kudo M
    Dig Dis; 2014; 32(6):705-10. PubMed ID: 25376287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An open-label, single-arm, phase I/II study of lower-dose decitabine based therapy in patients with advanced hepatocellular carcinoma.
    Mei Q; Chen M; Lu X; Li X; Duan F; Wang M; Luo G; Han W
    Oncotarget; 2015 Jun; 6(18):16698-711. PubMed ID: 25895027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib.
    Casadei Gardini A; Scarpi E; Faloppi L; Scartozzi M; Silvestris N; Santini D; de Stefano G; Marisi G; Negri FV; Foschi FG; Valgiusti M; Ercolani G; Frassineti GL
    Oncotarget; 2016 Oct; 7(41):67142-67149. PubMed ID: 27613839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
    Abou-Alfa GK; Schwartz L; Ricci S; Amadori D; Santoro A; Figer A; De Greve J; Douillard JY; Lathia C; Schwartz B; Taylor I; Moscovici M; Saltz LB
    J Clin Oncol; 2006 Sep; 24(26):4293-300. PubMed ID: 16908937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
    Abou-Alfa GK; Johnson P; Knox JJ; Capanu M; Davidenko I; Lacava J; Leung T; Gansukh B; Saltz LB
    JAMA; 2010 Nov; 304(19):2154-60. PubMed ID: 21081728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma.
    Abou-Alfa GK; Puig O; Daniele B; Kudo M; Merle P; Park JW; Ross P; Peron JM; Ebert O; Chan S; Poon TP; Colombo M; Okusaka T; Ryoo BY; Minguez B; Tanaka T; Ohtomo T; Ukrainskyj S; Boisserie F; Rutman O; Chen YC; Xu C; Shochat E; Jukofsky L; Reis B; Chen G; Di Laurenzio L; Lee R; Yen CJ
    J Hepatol; 2016 Aug; 65(2):289-95. PubMed ID: 27085251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
    Shahda S; Loehrer PJ; Clark RS; Spittler AJ; Althouse SK; Chiorean EG
    Oncologist; 2016 Jun; 21(6):664-5. PubMed ID: 27256874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06).
    Koeberle D; Montemurro M; Samaras P; Majno P; Simcock M; Limacher A; Lerch S; Kovàcs K; Inauen R; Hess V; Saletti P; Borner M; Roth A; Bodoky G
    Oncologist; 2010; 15(3):285-92. PubMed ID: 20203173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.